NDAORALTABLET, DELAYED RELEASE
Approved
Oct 2010
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
2
Data completeness
7/8 — Comprehensive
ATELVIA (risedronate sodium) by Teva is agent. Approved for osteoporosis, postmenopausal, osteoporosis. First approved in 2010.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ATELVIA is an oral delayed-release bisphosphonate containing risedronate sodium, approved in 2010 for treatment of postmenopausal osteoporosis and fracture prevention. The drug works by inhibiting osteoclast-mediated bone resorption, reducing bone turnover and strengthening skeletal structure. It is also used off-label in breast and prostate cancer patients at risk for bone complications.
$224KPart D
LOE ApproachingDeclining
1.7 years to LOEMinimal commercial activity with only 476 Part D claims in 2023 indicates a contracted franchise requiring defensive strategies ahead of 2028 LOE.
Mechanism of Action
agent. At the cellular level, risedronate inhibits osteoclasts. The osteoclasts adhere normally to the bone surface, but show evidence of reduced active resorption (for example, lack of ruffled border). Histomorphometry in rats, dogs, and minipigs showed that risedronate treatment reduces bone…
Indications (2)
Worked on ATELVIA at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.